Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2014, Article ID 719175, 12 pages
http://dx.doi.org/10.1155/2014/719175
Clinical Study

Postmastectomy Radiotherapy for Locally Advanced Breast Cancer Receiving Neoadjuvant Chemotherapy

1Department of Radiation-Oncology, University of Florence, Largo G. A. Brambilla 3, 50134 Florence, Italy
2Molecular and Nutritional Epidemiology Unit, ISPO (Cancer Research and Prevention Institute), University of Florence, Largo G. A. Brambilla 3, 50134 Florence, Italy
3Diagnostic Senology Unit, University of Florence, Largo G. A. Brambilla 3, 50134 Florence, Italy
4Department of Surgery, University of Florence, Largo G. A. Brambilla 3, 50134 Florence, Italy
5Department of Gynecology and Obstetrics, University of Florence, Largo G. A. Brambilla 3, 50134 Florence, Italy
6Department of Pathology, University of Florence, Largo G. A. Brambilla 3, 50134 Florence, Italy

Received 27 February 2014; Revised 7 May 2014; Accepted 21 May 2014; Published 22 June 2014

Academic Editor: An Liu

Copyright © 2014 Icro Meattini et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. J. S. D. Mieog, J. A. van der Hage, and C. J. H. van de Velde, “Neoadjuvant chemotherapy for operable breast cancer,” The British Journal of Surgery, vol. 94, no. 10, pp. 1189–1200, 2007. View at Publisher · View at Google Scholar · View at Scopus
  2. K. E. Hoffman, E. A. Mittendorf, and T. A. Buchholz, “Optimising radiation treatment decisions for patients who receive neoadjuvant chemotherapy and mastectomy,” The Lancet Oncology, vol. 13, no. 6, pp. e270–e276, 2012. View at Publisher · View at Google Scholar · View at Scopus
  3. M. E. Taylor, B. G. Haffty, R. Rabinovitch et al., “ACR appropriateness criteria on postmastectomy radiotherapy expert panel on radiation oncology-breast,” International Journal of Radiation Oncology Biology Physics, vol. 73, no. 4, pp. 997–1002, 2009. View at Publisher · View at Google Scholar · View at Scopus
  4. A. Goldhirsch, J. N. Ingle, R. D. Gelber, A. S. Coates, B. Thürlimann, and H.-J. Senn, “Thresholds for therapies: highlights of the St gallen international expert consensus on the primary therapy of early breast cancer 2009,” Annals of Oncology, vol. 20, no. 8, pp. 1319–1329, 2009. View at Publisher · View at Google Scholar · View at Scopus
  5. R. W. Carlson, D. C. Allred, B. O. Anderson et al., “Breast cancer. Clinical practice guidelines in oncology,” Journal of the National Comprehensive Cancer Network, vol. 7, no. 2, pp. 122–192, 2009. View at Google Scholar
  6. National Institute for Health Clinical Excellence, Early and Advanced Breast Cancer: Diagnosis and Treatment, NICE Clinical Guideline no. 80, NICE, London, UK, 2009.
  7. E. H. Huang, S. L. Tucker, E. A. Strom et al., “Postmastectomy radiation improves local-regional control and survival for selected patients with locally advanced breast cancer treated with neoadjuvant chemotherapy and mastectomy,” Journal of Clinical Oncology, vol. 22, no. 23, pp. 4691–4699, 2004. View at Google Scholar
  8. N. Bouzubar, K. J. Walker, K. Griffiths et al., “Ki67 immunostaining in primary breast cancer: pathological and clinical associations,” The British Journal of Cancer, vol. 59, no. 6, pp. 943–947, 1989. View at Google Scholar · View at Scopus
  9. M. E. H. Hammond, D. F. Hayes, A. C. Wolff, P. B. Mangu, and S. Temin, “American society of clinical oncology/college of American pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer,” Journal of Oncology Practice, vol. 6, no. 4, pp. 195–197, 2010. View at Publisher · View at Google Scholar · View at Scopus
  10. I. Meattini, L. Livi, C. Saieva et al., “Prognostic role of human epidermal growth factor receptor 2 status in premenopausal early breast cancer treated with adjuvant tamoxifen,” Clinical Breast Cancer, vol. 13, no. 4, pp. 247–253, 2013. View at Publisher · View at Google Scholar · View at Scopus
  11. L. Livi, I. Meattini, C. Saieva et al., “Prognostic value of positive human epidermal growth factor receptor 2 status and negative hormone status in patients with T1a/T1b, lymph node-negative breast cancer,” Cancer, vol. 118, no. 13, pp. 3236–3243, 2012. View at Publisher · View at Google Scholar · View at Scopus
  12. E. Munzone, E. Botteri, A. Sciandivasci et al., “Prognostic value of Ki-67 labeling index in patients with node-negative, triple-negative breast cancer,” Breast Cancer Research and Treatment, vol. 134, no. 1, pp. 277–282, 2012. View at Publisher · View at Google Scholar · View at Scopus
  13. M. Dowsett, T. O. Nielsen, R. A'Hern et al., “Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in breast cancer working group,” Journal of the National Cancer Institute, vol. 103, no. 22, pp. 1656–1664, 2011. View at Publisher · View at Google Scholar · View at Scopus
  14. E. H. Huang, S. L. Tucker, E. A. Strom et al., “Predictors of locoregional recurrence in patients with locally advanced breast cancer treated with neoadjuvant chemotherapy, mastectomy, and radiotherapy,” International Journal of Radiation Oncology Biology Physics, vol. 62, no. 2, pp. 351–357, 2005. View at Publisher · View at Google Scholar · View at Scopus
  15. M. Overgaard, P. S. Hansen, J. Overgaard et al., “Postoperative radiotherapy in high-risk premenopausal women with breast cancer who receive adjuvant chemotherapy,” The New England Journal of Medicine, vol. 337, no. 14, pp. 949–955, 1997. View at Publisher · View at Google Scholar · View at Scopus
  16. J. Ragaz, S. M. Jackson, N. Le et al., “Adjuvant radiotherapy and chemotherapy in node-positive premenopausal women with breast cancer,” The New England Journal of Medicine, vol. 337, no. 14, pp. 956–962, 1997. View at Publisher · View at Google Scholar · View at Scopus
  17. P. M. P. Poortmans, J. L. M. Venselaar, H. Struikmans et al., “The potential impact of treatment variations on the results of radiotherapy of the internal mammary lymph node chain: a quality-assurance report on the dummy run of EORTC phase III randomized trial 22922/10925 in stage I—III breast cancer,” International Journal of Radiation Oncology Biology Physics, vol. 49, no. 5, pp. 1399–1408, 2001. View at Publisher · View at Google Scholar · View at Scopus
  18. J. L. Wright, C. Takita, I. M. Reis et al., “Predictors of locoregional outcome in patients receiving neoadjuvant therapy and postmastectomy radiation,” Cancer, vol. 119, no. 1, pp. 16–25, 2013. View at Publisher · View at Google Scholar · View at Scopus
  19. L. Livi, C. Saieva, B. Detti et al., “Loco-regional recurrence in 2064 patients with breast cancer treated with mastectomy without adjuvant radiotherapy,” European Journal of Surgical Oncology, vol. 33, no. 8, pp. 977–981, 2007. View at Publisher · View at Google Scholar · View at Scopus
  20. E. A. Perez, V. J. Suman, N. E. Davidson et al., “Effect of doxorubicin plus cyclophosphamide on left ventricular ejection fraction in patients with breast cancer in the north central cancer treatment group N9831 intergroup adjuvant trial,” Journal of Clinical Oncology, vol. 22, no. 18, pp. 3700–3704, 2004. View at Publisher · View at Google Scholar · View at Scopus
  21. E. Tan-Chiu, G. Yothers, E. Romond et al., “Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31,” Journal of Clinical Oncology, vol. 23, no. 31, pp. 7811–7819, 2005. View at Publisher · View at Google Scholar · View at Scopus
  22. M. S. Ewer and J. A. O'Shaughnessy, “Cardiac toxicity of trastuzumab-related regimens in HER2-overexpressing breast cancer,” Clinical Breast Cancer, vol. 7, no. 8, pp. 600–607, 2007. View at Publisher · View at Google Scholar · View at Scopus
  23. M. L. Telli, S. A. Hunt, R. W. Carlson, and A. E. Guardino, “Trastuzumab-related cardiotoxicity: calling into question the concept of reversibility,” Journal of Clinical Oncology, vol. 25, no. 23, pp. 3525–3533, 2007. View at Publisher · View at Google Scholar · View at Scopus
  24. M. J. Piccart, J. Klijn, R. Paridaens et al., “Corticosteroids significantly delay the onset of docetaxel-induced fluid retention: final results of a randomized study of the European organization for research and treatment of cancer investigational drug branch for breast cancer,” Journal of Clinical Oncology, vol. 15, no. 9, pp. 3149–3155, 1997. View at Google Scholar · View at Scopus
  25. R. K. Ramanathan, V. V. Reddy, J. M. Holbert, and C. P. Belani, “Pulmonary infiltrates following administration of paclitaxel,” Chest, vol. 110, no. 1, pp. 289–292, 1996. View at Google Scholar · View at Scopus
  26. W. L. Read, J. E. Mortimer, and J. Picus, “Severe interstitial pneumonitis associated with docetaxel administration,” Cancer, vol. 94, no. 3, pp. 847–853, 2002. View at Publisher · View at Google Scholar · View at Scopus
  27. S. E. McGuire, A. M. Gonzalez-Angulo, E. H. Huang et al., “Postmastectomy radiation improves the outcome of patients with locally advanced breast cancer who achieve a pathologic complete response to neoadjuvant chemotherapy,” International Journal of Radiation Oncology Biology Physics, vol. 68, no. 4, pp. 1004–1009, 2007. View at Publisher · View at Google Scholar · View at Scopus
  28. B. L. Fowble, J. P. Einck, D. N. Kim et al., “Role of postmastectomy radiation after neoadjuvant chemotherapy in stage II-III breast cancer,” International Journal of Radiation Oncology Biology Physics, vol. 83, no. 2, pp. 494–503, 2012. View at Publisher · View at Google Scholar · View at Scopus
  29. J. L. Oh, M. J. Dryden, W. A. Woodward et al., “Locoregional control of clinically diagnosed multifocal or multicentric breast cancer after neoadjuvant chemotherapy and locoregional therapy,” Journal of Clinical Oncology, vol. 24, no. 31, pp. 4971–4975, 2006. View at Publisher · View at Google Scholar · View at Scopus
  30. A. K. Garg, J. L. Oh, M. J. Oswald et al., “Effect of postmastectomy radiotherapy in patients <35 years old with stage II-III breast cancer treated with doxorubicin-based neoadjuvant chemotherapy and mastectomy,” International Journal of Radiation Oncology Biology Physics, vol. 69, no. 5, pp. 1478–1483, 2007. View at Publisher · View at Google Scholar · View at Scopus
  31. M. E. Straver, E. J. T. Rutgers, S. Rodenhuis et al., “The relevance of breast cancer subtypes in the outcome of neoadjuvant chemotherapy,” Annals of Surgical Oncology, vol. 17, no. 9, pp. 2411–2418, 2010. View at Publisher · View at Google Scholar · View at Scopus
  32. C. Liedtke, C. Mazouni, K. R. Hess et al., “Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer,” Journal of Clinical Oncology, vol. 26, no. 8, pp. 1275–1281, 2008. View at Publisher · View at Google Scholar · View at Scopus
  33. R. Bhargava, S. Beriwal, D. J. Dabbs et al., “Immunohistochemical surrogate markers of breast cancer molecular classes predicts response to neoadjuvant chemotherapy: a single institutional experience with 359 cases,” Cancer, vol. 116, no. 6, pp. 1431–1439, 2010. View at Publisher · View at Google Scholar · View at Scopus
  34. W. F. Symmans, F. Peintinger, C. Hatzis et al., “Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy,” Journal of Clinical Oncology, vol. 25, no. 28, pp. 4414–4422, 2007. View at Publisher · View at Google Scholar · View at Scopus
  35. E. P. Mamounas, G. Tang, B. Fisher et al., “Association between the 21-gene recurrence score assay and risk of locoregional recurrence in node-negative, estrogen receptor-positive breast cancer: results from NSABP B-14 and NSABP B-20,” Journal of Clinical Oncology, vol. 28, no. 10, pp. 1677–1683, 2010. View at Publisher · View at Google Scholar · View at Scopus
  36. H. Nagar, E. A. Mittendorf, E. A. Strom et al., “Local-regional recurrence with and without radiation therapy after neoadjuvant chemotherapy and mastectomy for clinically staged T3N0 breast cancer,” International Journal of Radiation Oncology Biology Physics, vol. 81, no. 3, pp. 782–787, 2011. View at Publisher · View at Google Scholar · View at Scopus
  37. T. A. Buchholz, C. D. Lehman, J. R. Harris et al., “Statement of the science concerning locoregional treatments after preoperative chemotherapy for breast cancer: a national cancer institute conference,” Journal of Clinical Oncology, vol. 26, no. 5, pp. 791–797, 2008. View at Publisher · View at Google Scholar · View at Scopus